一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
免疫检查点抑制剂治疗非小细胞肺癌诱发的细胞因子释放综合征
英文原题：Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
查看英文原题
Cytokine Release Syndrome Induced by Immune-checkpoint Inhibitor Therapy for Non-small-cell Lung Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
免疫相关不良事件，包括自身免疫毒性，可能作为免疫检查点抑制剂（ICI）癌症治疗的结果而出现。细胞因子释放综合征（CRS）是一种严重且危及生命的细胞因子相关毒性，可在过继性T细胞治疗后发生。我们在此报告一例晚期非小细胞肺癌ICI治疗后发生严重CRS的罕见病例。他在第一疗程程序性死亡配体-1抑制剂和铂类双药化疗后出现持续高热、心源性休克和弥散性血管内凝血。他通过类固醇冲击治疗和tocilizumab恢复。CRS是ICI治疗罕见但危及生命的不良事件，因此值得警惕。
展开英文摘要原文
Immune-related adverse events, including autoimmune toxicity, may develop as a consequence of immune-checkpoint inhibitor (ICI) cancer therapy. Cytokine release syndrome (CRS) is a severe and life-threatening cytokine-associated toxicity that can develop after adoptive T-cell therapy.
We herein report a rare case of severe CRS after ICI therapy for advanced non-small-cell lung cancer. He presented with a prolonged high fever, cardiogenic shock, and disseminated intravascular coagulation after the first course of programed death ligand-1 inhibitor and platinum-based doublet chemotherapy. He recovered by steroid pulse therapy and tocilizumab. CRS is a rare but life-threatening adverse event of ICI therapy and therefore warrants awareness.
论文信息
- 作者
- Yomota M、Mirokuji K、Sakaguchi M、Kitahara Y、Chin F、Setoguchi K、Hosomi Y
- 单位
- Department of Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan.Japan
- 文献类型
- 病例报告
- 期刊
- Internal medicine (Tokyo, Japan)2021 Nov 1
- 原文标识
- PubMed 33775995 · DOI 10.2169/internalmedicine.5922-20
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →